Related Experiment Video
Updated: Dec 13, 2025
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with
Farah Nawaz1, Ozair Alam1, Ahmad Perwez2
1Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India.
Background:
The Epidermal Growth Factor Receptor (known as EGFR) induces cell differentiation and proliferation upon activation through the binding of its ligands. Since EGFR is thought to be involved in the development of cancer, the identification of new target inhibitors is the most viable approach, which recently gained momentum as a potential anticancer therapy.
Objective:
To assess various pyrazole linked pyrazoline derivatives with carbothioamide for EGFR kinase inhibitory as well as anti-proliferative activity against human cancer cell lines viz. A549 (non-small cell lung tumor), MCF-7 (breast cancer cell line), SiHa (cancerous tissues of the cervix uteri), and HCT-116 (colon cancer cell line).
Methods:
In vitro EGFR kinase assay, in vitro MTT assay, Lactate dehydrogenase release, nuclear staining (DAPI), and flow cytometry cell analysis.
Results:
Compounds 6h and 6j inhibited EGFR kinase at concentrations of 1.66μM and 1.9μM, respectively. Furthermore, compounds 6h and 6j showed the most potent anti-proliferative results against the A549 KRAS mutation cell line (IC50 = 9.3 & 10.2μM). Through DAPI staining and phase contrast microscopy, it was established that compounds 6h and 6j also induced apoptotic activity in A549 cells. This activity was further confirmed by FACS using Annexin-V-FITC and Propidium Iodide (PI) labeling. Molecular docking studies performed on 6h and 6j suggested that the compounds can bind to the hinge region of ATP binding site of EGFR tyrosine kinase in a similar pose as that of the standard drug gefitinib.
Conclusion:
The potential anticancer activity of compounds 6h and 6j was confirmed and need further exploration in cancer cell lines of different tissue origin and signaling pathways, as well as in animal models of cancer development.
Insights
New pyrazole derivatives (6h and 6j) show potent anticancer activity by inhibiting Epidermal Growth Factor Receptor (EGFR) kinase and inducing apoptosis in cancer cells. Further research is warranted for diverse cancer models.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Oncology
Background:
- Epidermal Growth Factor Receptor (EGFR) signaling drives cell proliferation and differentiation.
- EGFR dysregulation is implicated in cancer development, necessitating novel targeted inhibitors.
- Targeting EGFR represents a promising strategy for anticancer therapy.
Purpose of the Study:
- To synthesize and evaluate pyrazole linked pyrazoline derivatives with carbothioamide for EGFR kinase inhibitory activity.
- To assess the anti-proliferative effects of these compounds against various human cancer cell lines.
- To investigate the mechanism of action, including apoptosis induction.
Main Methods:
- In vitro EGFR kinase inhibition assays.
- In vitro MTT assays for anti-proliferative activity.
- Apoptosis assays (DAPI staining, flow cytometry with Annexin-V-FITC/PI).
- Molecular docking studies to predict binding interactions.
Main Results:
- Compounds 6h and 6j demonstrated significant EGFR kinase inhibition (1.66μM and 1.9μM).
- These compounds exhibited potent anti-proliferative activity against A549 cells (IC50 = 9.3 & 10.2μM).
- Compounds 6h and 6j induced apoptosis in A549 cells and showed favorable binding to the EGFR ATP site.
Conclusions:
- Compounds 6h and 6j possess confirmed anticancer potential via EGFR inhibition and apoptosis induction.
- Further investigation in diverse cancer types and in vivo models is recommended.
- These derivatives represent promising leads for developing novel EGFR-targeted cancer therapies.
More Related Videos
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...